Edition:
United States

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

1.93USD
11:36am EDT
Change (% chg)

$-0.01 (-0.52%)
Prev Close
$1.94
Open
$1.95
Day's High
$1.96
Day's Low
$1.91
Volume
27,094
Avg. Vol
241,065
52-wk High
$3.31
52-wk Low
$1.30

Select another date:

Thu, Jun 22 2017

BRIEF-FDA gives "orphan drug" status to Idera's skin cancer drug

* Idera announces FDA orphan drug designation for IMO-2125 for the treatment of melanoma

HGGC to buy majority stake in Idera, values firm over $1 billion

SAN FRANCISCO HGGC has agreed to take a majority stake in database software firm Idera, valuing the company at roughly $1.125 billion including debt, the private equity firm said in a statement.

UPDATE 1-HGGC to buy majority stake in Idera, values firm over $1 bln

SAN FRANCISCO, May 31 HGGC has agreed to take a majority stake in database software firm Idera, valuing the company at roughly $1.125 billion including debt, the private equity firm said in a statement.

HGGC to buy majority stake in Idera, values firm over $1 bln: sources

SAN FRANCISCO, May 31 Private equity firm HGGC has agreed to take a majority stake in database software firm Idera, valuing the company at roughly $1.125 billion including debt, according to sources familiar with the matter.

BRIEF-Idera Pharmaceuticals reports Q1 loss per share $0.10

* Idera Pharmaceuticals reports first quarter 2017 financial results and provides corporate update

BRIEF-Idera Pharmaceuticals announces organizational update

* Idera Pharmaceuticals announces organizational update Source text for Eikon: Further company coverage:

BRIEF-Idera Pharmaceuticals advances investigational treatment for unmet need in anti-PD-1 refractory metastatic melanoma

* Idera Pharmaceuticals advances investigational treatment – intratumoral IMO-2125 in combination with ipilimumab - for unmet need in anti-PD-1 refractory metastatic melanoma

BRIEF-Idera Pharmaceuticals reports Q4 earnings per share $0.01

* Idera Pharmaceuticals reports fourth quarter and year end 2016 financial results and provides corporate update

BRIEF-Idera Pharma reports positive Phase 1 data for IMO-2125

* Idera Pharmaceuticals presents update from ongoing phase 1 dose escalation clinical trial of Intratumoral IMO-2125 in combination with Ipilimumab in metastatic melanoma patients refractory to Anti-PD-1 treatment at the 2017 ASCO-SITC clinical Immuno-Oncology Symposium

Select another date: